# OnCo record nct06764186 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06764186/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06764186", "NCT06764186" ;
  schema:name "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain"@en ;
  schema:alternateName "CAPItana"@en ;
  schema:description "A phase 3 trial of Fulvestrant and Capivasertib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06764186/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06764186> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-01-07" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/capivasertib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .